Trial reportThe Journal of allergy and clinical immunology2026
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies.
Trial report in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Oral Food Challenges After Treatment With Omalizumab in the Clinical Setting.The journal of allergy and clinical immunology. In practice · 2026Article
- Almond Allergy in Children and Adults: A Narrative Review of Current Knowledge, Clinical Challenges, and Research Gaps.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
backgroundStage 1 of the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH) study demonstrated that treatment with omalizumab for 16 to 20 weeks significantly increased the reaction threshold for peanut and other common food allergens in participants with multiple food allergies. However, the degree of this protection is variable across participants, and there are no known markers to predict or assess individual response to omalizumab.
objectiveOur aim was to evaluate clinical and laboratory-based variables as predictors or correlates of response to omalizumab treatment.
methodsCumulative tolerated dose (CTD) as a continuous variable and thresholds of 444 mg and 1044 mg of individual food proteins were selected as definitions of positive treatment response. Clinical and immunologic variables were evaluated as predictors of response.
resultsOmalizumab treatment reduced the level of free IgE. In this exploratory analysis (N = 116), although not definitive, higher total IgE level at baseline was the most consistent predictor of a positive response to omalizumab treatment (peanut CTD: r = 0.25; q = 0.047). Omalizumab dosing frequency (every 2 weeks) was also associated with higher peanut CTD outcomes (r = 0.25; q = 0.047). Medical history of allergy, level of allergen-specific IgE, skin prick test result, and basophil activation did not consistently correlate with response to omalizumab treatment. Concomitant peanut and milk allergy was positively correlated with outcomes of omalizumab treatment (r = 0.34; q = 0.003), whereas peanut allergy concomitant with either cashew allergy (r = -0.43; q = 0.003) or walnut allergy (r = -0.26; q = 0.042) was inversely correlated with outcomes of omalizumab treatment.
conclusionOf the food allergy biomarkers and omalizumab dosing assessed in this analysis, a higher baseline total IgE level was the most consistent, albeit modest, predictor of successful peanut threshold protection with omalizumab treatment, thus warranting further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.